Results 81 to 90 of about 495 (142)

Availability of New Medicines in the US and Germany From 2004 to 2018.

JAMA Netw Open, 2022
Blankart K, Naci H, Chandra A.
europepmc   +1 more source

AMNOG-Erkenntnisse in Leitlinien [PDF]

, 2016
Fleer, D, Schell, LK, Kaiser, T
core   +1 more source

AMNOG: Aktuelle gesundheitsökonomische Aspekte [PDF]

, 2020
Volker Ulrich, Matthias J. Kaiser
core   +1 more source

[Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps]. [PDF]

HNO, 2021
Klimek L, Chaker A, Deitmer T, Plontke SK, Wollenberg B, Bousquet J, Bachert C.   +6 more
europepmc   +1 more source

AMNOG – gut gedacht, schlecht gemacht? AMNOG-Verfahren und regionale Ebene [PDF]

, 2018
Susanne Braun, Katharina Brüderl
core   +1 more source

Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose. [PDF]

Eur J Health Econ
Schweitzer MK, Dold MN, Genet A, Gossens K, Klein-Hessling T, Löffler N, Rabel M, Rasch A, Reuter EM, Schmelcher J, Wolfram N, Werner S.   +11 more
europepmc   +1 more source

Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting. [PDF]

J Pharm Policy Pract
d'Errico M, Giannarelli D, d'Angela D, Pinto C, Polistena B, Spandonaro F.   +5 more
europepmc   +1 more source

AMNOG und Rechtsschutzmöglichkeiten [PDF]

, 2012
Christian Stallberg
core   +1 more source

Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China. [PDF]

Regen Ther
Shi J, Hu H, Ung COL.
europepmc   +1 more source

AMNOG-Check 2017 [PDF]

, 2017
Volker Ulrich, Dieter Cassel
core   +1 more source